Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma

Esophagogastric Junction Adenocarcinoma Clinical Trial

Official title:
Neoadjuvant Sintilimab Plus SOX in the Locally Advanced Esophagogastric Junction Adenocarcinoma: a Prospective, Single Arm Phase II Trial

Status Recruiting

Clinical Trial Summary

The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction adenocarcinoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Esophagogastric Junction Adenocarcinoma

Clinical Trial Details

NCT number	NCT05170503
Study type	Interventional
Source	Sun Yat-sen University
Contact	Hong Yang, M.D. Ph.D.
Phone	+8613560405144
Email	yanghong@sysucc.org.cn
Status	Recruiting
Phase	Phase 2
Start date	December 29, 2021
Completion date	January 1, 2029

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT05001360` - Study of FMT Combined With Nivolumab in Gastric Cancer	N/A
Enrolling by invitation	`NCT04153058` - Clinical Outcomes of Robotic Versus Laparoscopic Assisted Radical Gastrectomy for Advanced Siewert II/III AEG	N/A
Recruiting	`NCT04423354` - A Prospective Clinical Study of Transthoracic Single-hole Assisted Laparoscopic Radical Gastrectomy for Siewert Ⅱ AEG	N/A
Completed	`NCT00719550` - AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer	Phase 1/Phase 2